✦ LIBER ✦

P-313 Response and progression rate of patients with primary MDS and isolated del(5q), IPSS low/int1 under treatment with lenalidomide

✍ Scribed by Germing, U.; Giagounidis, A.; Büsche, G.; Platzbecker, U.; Götze, K.; Nolte, F.; Schlenk, R.F.; Letsch, A.; Ganser, A.; Lübbert, M.; Bug, G.; Schafhausen, P.; Schemenau, J.; Haase, D.

Book ID: 122352281
Publisher: Elsevier Science
Year: 2013
Tongue: English
Weight: 65 KB
Volume: 37
Category: Article
ISSN: 0145-2126
DOI: 10.1016/S0145-2126(13)70360-6

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

P-104 Outcomes by IPSS-R in lenalidomide

P-104 Outcomes by IPSS-R in lenalidomide-treated patients with IPSS low-/Int-1-risk MDS With del(5q) in MDS-003 and MDS-004: A retrospective analysis

✍ Sekeres, M.; Swern, A.; Fenaux, P.; Greenberg, P.; Sanz, G.; Bennett, J.; Dreyfu 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 399 KB

P-023 Incidence and prognostic value of

P-023 Incidence and prognostic value of TP53 mutations in IPSS low and INT 1 (lower risk) MDS with del 5q

✍ Bally, C.; Ades, L.; Renneville, A.; Preudhomme, C.; Raynaud, S.; Cluzeau, T.; E 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 112 KB